STOCK TITAN

ALKS: CFO Granted 158,743 Options and 36,656 RSUs on 10/08/2025

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Joshua Reed, SVP and Chief Financial Officer, reported equity awards in a Form 4 filed for Alkermes plc (ALKS). On 10/08/2025 he was granted an employee stock option covering 158,743 ordinary shares with an exercise price of $31.51 and a restricted stock unit (RSU) award for 36,656 ordinary shares. Both awards were reported as acquired on the same date and are direct holdings. The option shares vest in four equal annual installments beginning 10/08/2026, and the RSUs vest on the same four-year schedule. Following the transactions, Mr. Reed beneficially owns 158,743 options and 36,656 RSUs. The Form 4 was signed on 10/10/2025.

Positive

  • Significant equity grant aligns CFO interests with shareholders via long-term vesting
  • Mix of options and RSUs balances upside participation ($31.51 strike) with guaranteed vested value from RSUs

Negative

  • Potential future dilution from 158,743 options and 36,656 RSUs if/when vested and exercised
  • Concentration of executive compensation tied to equity may increase reported dilution and compensation expense over vesting period

Insights

Grant ties CFO to long-term shareholder value via multi-year vesting.

Equity awards with four-year annual vesting schedules align the executive's compensation with multi-year performance and retention objectives. The grant date of 10/08/2025 and the vesting start of 10/08/2026 create a clear multi-period incentive horizon.

Dependencies include future share-price performance and continued service through each vesting date; these awards do not create immediate dilution but will convert to ordinary shares over time as they vest and options are exercised. Monitor annual vesting cliffs and combined outstanding share impact over the next four years.

Grant size and mix indicate typical senior exec package: options plus RSUs.

The award combines 158,743 options at an exercise price of $31.51 with 36,656 RSUs, a common mix intended to reward upside while providing guaranteed equity value on vesting for retention. The RSUs convert to one ordinary share each upon vesting.

Risks include potential future dilution if options are exercised and timing of recognition for accounting expense. Watch for related disclosures in periodic filings showing share-count and compensation expense over the next fiscal year.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reed Joshua

(Last) (First) (Middle)
900 WINTER ST.

(Street)
WALTHAM MA 02451

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Alkermes plc. [ ALKS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $31.51 10/08/2025 A 158,743 (1) 10/08/2035 Ordinary Shares 158,743 $0 158,743 D
Restricted Stock Unit Award (2) 10/08/2025 A 36,656 (3) (3) Ordinary Shares 36,656 $0 36,656 D
Explanation of Responses:
1. Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 10/8/2026.
2. Each restricted stock unit represents a contingent right to receive one ordinary share.
3. Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 10/8/2026.
/s/ Shantale Greenson, attorney-in-fact for Joshua Reed 10/10/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Alkermes (ALKS) CFO Joshua Reed receive on 10/08/2025?

He was granted an employee stock option for 158,743 shares at an exercise price of $31.51 and 36,656 restricted stock units (RSUs).

When do the awarded options and RSUs vest?

Both the options and the RSUs vest in four equal annual installments commencing on 10/08/2026.

How many securities does Joshua Reed beneficially own after the reported transactions?

Following the reported transactions he beneficially owns 158,743 options and 36,656 RSUs.

What is the exercise price of the options granted to the CFO?

The employee stock option has an exercise price of $31.51 per share.

When was the Form 4 signed and filed?

The Form 4 shows the signature date as 10/10/2025, reporting transactions dated 10/08/2025.
Alkermes Plc

NASDAQ:ALKS

ALKS Rankings

ALKS Latest News

ALKS Latest SEC Filings

ALKS Stock Data

4.70B
161.97M
1.49%
104.97%
8.06%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 4